Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q3 2014 · 10-Q
Revenue$9.73M$9.73M+49.0% vs Q3 2013 Net Income$745.92K$745.92KN/M vs Q3 2013 EPS Diluted$0.04$0.04N/M vs Q3 2013 Operating Income$989,038N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$2,037,318N/M Margins · derivedOperating margin10.2%+33.4 pt vs Q3 2013
Net margin7.7%+20.2 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 7, 2014 · 38 d after period end